New hope for tough pancreatic cancer cases in early drug trial
NCT ID NCT03854110
Summary
This is a first-in-human study to find a safe dose of a new drug, GP-2250, when given with the chemotherapy gemcitabine. It is for adults with advanced pancreatic cancer that has continued to grow despite prior treatment. The main goal is to check for side effects and see how the body processes the drug, while also looking for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center at the University of Pennsylvania
Phildelphia, Pennsylvania, 19104, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Hoag Family Cancer Institute
Newport Beach, California, 92663, United States
-
University of Kansas Cancer Center
Fairway, Kansas, 66205, United States
-
Wake Forest Baptist Health
Winston-Salem, North Carolina, 27292, United States
Conditions
Explore the condition pages connected to this study.